Loqtorzi 240 mg/6 mL (40 mg/mL) injection Images
Generic Name: toripalimab
This medication has been identified as Loqtorzi 240 mg/6 mL (40 mg/mL) injection. It is supplied by Coherus BioSciences, Inc.
Loqtorzi is used in the treatment of Nasopharyngeal Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Loqtorzi 240 mg/6 mL (40 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Loqtorzi
- Generic Name
- toripalimab
- Strength
- 240 mg/6 mL (40 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Coherus BioSciences, Inc.
- National Drug Code (NDC)
- 70114-0340
See also:
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Platinol
Platinol is used for bladder cancer, blood cell transplantation, bone marrow transplantation, brain ...
More about Loqtorzi (toripalimab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.